Hematologic Oncology Update

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:

• Introduction (0:00)
• Minimal Residual Disease Assays in Community-Based Practice (1:24)
• New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)
• Richter Transformation (30:43)
• Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)

CME information and select publications

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

• Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
• Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
• Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
• Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
• Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
• Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• First-Line Treatment (1:33)
• Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• First-Line Therapy (2:48)
• Relapsed/Refractory Disease (39:30)

CME information and select publications

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:

• Introduction (0:00)
• Trials in Progress (1:12)
• Chronic Lymphocytic Leukemia (7:09)
• Diffuse Large B-Cell Lymphoma (32:35)
• Mantle Cell Lymphoma (58:25)
• Follicular Lymphoma (1:14:49)

CME information and select publications

Featuring an interview with Dr Douglas W Sborov, including the following topics:

• DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
• Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
• Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
• Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
• Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
• Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
• Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
• Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
• Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)

CME information and select publications

Featuring an interview with Prof Andreas Hochhaus, including the following topics:

• Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
• Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
• Potential mechanisms of adverse events documented with TKIs (10:23)
• Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
• Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
• Comparative efficacy of asciminib and other agents used to treat CML (40:01)
• Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
• Practical care strategies for CML patients; future developments (52:32)

CME information and select publications

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

• Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
• Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
• Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)

CME information and select publications

Featuring perspectives from Prof John Seymour, including the following topics:

• Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
• Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
• First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)

CME information and select publications

Featuring perspectives from Dr William G Wierda, including the following topics:

• Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)
• Sequencing Road Map (12:39)
• Key Datasets — Pirtobrutinib (21:08)
• Investigator Survey (34:09)
• Chimeric Antigen Receptor T-Cell Therapy (45:08)
• Other Novel Therapy Approaches (49:58)
• EHA 2026 (54:45)

CME information and select publications